Jean-philippe P. Camdessanche

Saint-etienne-de-valoux, 42055, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Tofersen Treatment in SOD1-ALS: Real-World Evidence from a Retrospective Multicenter Study in France (FORSLA Study).

Tofersen Treatment in SOD1-ALS: Real-World Evidence from a Retrospective Multicenter Study in France (FORSLA Study).

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes

Published: August 04, 2026

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Journal: Annals of clinical and translational neurology

Published: June 12, 2026

Clinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorder.

Clinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorder.

Journal: Neurology

Published: May 15, 2026

Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study.

Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 06, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: May 05, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

Tick-borne encephalitis emergence as the third leading cause of encephalitis/meningoencephalitis in western Auvergne-Rhône-Alpes, France.

Tick-borne encephalitis emergence as the third leading cause of encephalitis/meningoencephalitis in western Auvergne-Rhône-Alpes, France.

Journal: Infectious diseases now

Published: February 16, 2026

Revisiting the didactic diagram of peripheral neuropathies: Two decades of progress.

Revisiting the didactic diagram of peripheral neuropathies: Two decades of progress.

Journal: Neurophysiologie clinique = Clinical neurophysiology

Published: January 18, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Journal: CNS drugs

Published: September 04, 2025

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

Journal: JAMA neurology

Published: August 04, 2025

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Journal: Neurology

Published: July 30, 2025

Showing 1-12 of 136

Last Updated: 09/26/2026